Platelet mitochondrial dysfunction and mitochondria-targeted quinone-and hydroquinone-derivatives: Review on new strategy of antiplatelet activity.

Abstract

Platelet mitochondrial dysfunction has been identified in different diseases. Platelet mitochondrial dysfunction favors platelet activation with a considerable increase in oxidative stress, which is implicated in platelet non-responsiveness to current antiplatelet therapy. The inhibition of platelet mitochondrial dysfunction could potentially be used as a new strategy for the development of antiplatelet activity drugs. In this context, we described quinone and hydroquinone derivatives and mitochondrially targeted compounds as initial precursors for the synthesis of new antiplatelet agents.

• Authors: Manuel Fuentes, Ramiro Araya-Maturana, Iván Palomo, Eduardo Fuentes
• Journal: Biochemical pharmacology (Biochem Pharmacol) Vol. 156 Pg. 215-222 (10 2018) ISSN: 1873-2968 [Electronic] England
• PMID: 30149016 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Hydroquinones
• Platelet Aggregation Inhibitors
• Quinones

Topics

• Animals
• Blood Platelets (drug effects, metabolism)
• Humans
• Hydroquinones (chemistry, pharmacology)
• Mitochondria (drug effects, metabolism)
• Platelet Aggregation Inhibitors (pharmacology)
• Quinones (chemistry, pharmacology)